Compartmental modeling of 11C-HOMADAM binding to the serotonin transporter in the healthy human brain.

Department of Radiology, Emory University, Atlanta, Georgia, USA.
Journal of Nuclear Medicine (Impact Factor: 5.56). 01/2009; 49(12):2018-25. DOI: 10.2967/jnumed.108.054262
Source: PubMed

ABSTRACT The novel PET radioligand (11)C-N,N-dimethyl-2-(2'-amino-4'-hydroxymethylphenylthio)benzylamine ((11)C-HOMADAM) binds with high affinity and selectively to the serotonin transporter (SERT). The purpose of this study was to develop a reliable kinetic model to describe the uptake of (11)C-HOMADAM in the healthy human brain.
Eight volunteers participated in the study; 5 of them were fitted with arterial catheters for blood sampling and all were scanned on a high-resolution research tomograph after the injection of (11)C-HOMADAM. Regional distribution volumes and binding potentials were calculated with 2- and 4-parameter arterial-input compartment models, a 3-parameter reference tissue compartment model, and the Logan graphic approach.
The 2-parameter arterial-input compartment model was statistically superior to the 4-parameter model and described all brain regions. Calculated binding potentials agreed well between the arterial-input model and the reference tissue model when the cerebellum was used as the reference tissue. The Logan graphic approach was not able to estimate the higher concentration of SERT in the dorsal raphe than in the midbrain.
(11)C-HOMADAM is a highly promising radioligand with high ratios of specific binding to nonspecific binding in known SERT-rich structures, such as the raphe nuclei. The 3-parameter reference tissue model approach permits a simplified quantitatively accurate method for estimating SERT binding potentials.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Two novel radioligands for the serotonin transporter (SERT), [125I]{3-[5-iodo-1-[4-fluorophenyl)-1,3-dihydroisobenzofuran-1-yl]-propyl}-dimethylamine ([125I]-2) and S-[125I]{3-[5-iodo-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-1-yl]-propyl}-dimethylamine ([125I]-(S)-2) were synthesized in a Br/125I exchange reaction. Binding experiments in rats yielded Kd values of 0.7 ± 0.06 and 0.52 ± 0.02 nM for [125I]-2 and [125I]-(S)-2, respectively. One hour after intravenous injection of [125I]-2, 0.34% of the injected dose had accumulated in the brain. The highest hypothalamus-to-cerebellum ratio was reached 2 h after injection of [125I]-(S)-2 and amounted to 2.4. Pre-treatment experiments with paroxetine resulted in effective reduction of the target-to-cerebellum ratios.The corresponding iodine-123 labelled compound S-[123I]{3-[5-Iodo-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-1-yl]-propyl}-dimethylamine [123I]-S-2 was investigated in a pig single photon emission computed tomography (SPECT) study. Between 60 and 110 min after IV injection, the midbrain-to-cerebellum ratio was 1.2. However, the uptake did not differ between high-density and medium-density regions questioning the feasibility of the radioligand in imaging cortical SERT distribution in vivo.These data suggest that the iodine-labelled derivatives of citalopram and escitalopram are not superior to another SPECT tracer for the SERT, namely [123I]ADAM. Copyright © 2010 John Wiley & Sons, Ltd.
    Journal of Labelled Compounds 04/2011; 54(4).
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We present a fully Bayesian statistical approach to the problem of compartmental modelling in the context of Positron Emission Tomography. We cluster homogeneous region of interest and perform kinetic parameter estimation simultaneously. A mixture modelling approach is adopted, incorporating both spatial and temporal information based on reconstructed dynamic PET image. Our modelling approach is flexible, and provides uncertainty estimates for the estimated kinetic parameters. Crucially, the proposed method allows us to determine the unknown number of clusters, which has a great impact on resulting estimated kinetic parameters. We demonstrate our method on simulated dynamic Myocardial PET data, and show that our method is superior to standard curve-fitting approach.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The serotonin transporter (SERT) has been implicated in a variety of neuropsychiatric disorders including depression, anxiety, and suicide, and is the target of the selective serotonin reuptake inhibitor (SSRI) class of antidepressants. The availability of SERT-specific positron emission tomography (PET) radioligands will allow the SERT to be studied noninvasively in living subjects through PET imaging of the SERT and occupancy studies of SSRIs. Numerous diaryl sulfide and tropane derivatives have been developed and radiolabeled with (11) C or (18) F for imaging the SERT with PET.
    Journal of Labelled Compounds 03/2013; 56(3-4):114-119.